Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
Status:
Completed
Trial end date:
2012-01-25
Target enrollment:
Participant gender:
Summary
This is a phase 1b study to evaluate the combination of gemcitabine and Tarceva (erlotinib)
and nab-paclitaxel in patients with advanced pancreatic cancer.